Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Omega-7, particularly palmitoleic acid, has gained attention for its potential benefits in supporting metabolic health, including metabolic syndrome—a cluster of conditions that increase the risk for heart disease, stroke, and type 2 diabetes. The scientific evidence for its use is emerging but remains limited and preliminary. Several small-scale human studies and animal models suggest that palmitoleic acid may improve insulin sensitivity, reduce inflammation, and help regulate lipid metabolism, all factors relevant to metabolic syndrome. For example, a 2014 randomized controlled trial published in the journal Lipids in Health and Disease found that supplementation with purified palmitoleic acid improved insulin sensitivity and decreased CRP (a marker of inflammation) in adults with elevated triglycerides. Other studies have observed potential reductions in LDL cholesterol and improvements in other markers of metabolic health.

However, these studies often involve small sample sizes, short durations, and sometimes conflicting results. There is a lack of large-scale, long-term clinical trials establishing clear efficacy or safety for Omega-7 supplementation in the management or prevention of metabolic syndrome. The American Heart Association and other major medical bodies do not currently recommend Omega-7 as a treatment for metabolic syndrome due to insufficient evidence. In summary, while the use of Omega-7 for metabolic syndrome has some scientific basis, the evidence is weak to moderate and not yet conclusive.

More about Omega-7
More about Metabolic Syndrome

Other ingredients used for Metabolic Syndrome

Other health conditions supported by Omega-7

Products containing Omega-7